OFAT versus DOE as two optimization protocols for the chromatographic analysis of some OTC pharmaceuticals carrying negative cardiovascular effects and administered by pregnant and breast-feeding females: Application to dose dependent effect

• Autorzy: El Sherbiny Dina , Wahba Mary E. K.

Identyfikatory

DOI

10.1556/1326.2020.00708

• Języki publikacji: EN

Abstrakty

EN

A simple HPLC technique has been utilized for rapid and sensitive quantitative analysis of two mixtures of drugs that are used during pregnancy and lactation. Drugs of the first mixture are used to manage gastrointestinal tract illness that are common during early stages of pregnancy, while pharmaceutical agents of the second mixture are administered over the counter as galactagogues or to overcome postpartum depression. Mixture I includes famotidine (FMT), ranitidine (RNT), nizatidine (NZT), and pantoprazole (PNT), which were separated on a C18 column using a mobile phase composed of methanol: 0.02 M sodium dihydrogen phosphate (60:40, v/v) of pH 6.9, adopting UV detection at 240 nm at a flow rate of 1 mL/min. Mixture II on the other hand, consists of domperidone (DOM), metoclopramide (MET), and sulpiride (SUL). These drugs were eluted using the same column and flow rate as those in mixture I, using a mobile phase consisting of acetonitrile: 0.075 M sodium dihydrogen phosphate (30:70, v/v) of pH 6 adopting a detection wavelength 270 nm. Two optimization protocols were utilized to optimize the chromatographic separation conditions, namely one factor at a time (OFAT) and design of experiments (DOE) where face centered cube response surface experimental design was chosen for this investigation. Comparison of the results obtained from both protocols reveals the accordance between them. Full validation procedure under guidance of United States Pharmacopoeia (USP) was applied to the proposed methods which enabled their application to separate the drugs of both mixtures in spiked rat whole blood samples and in vivo analysis of rat heart blood.

Słowa kluczowe

EN

pregnancy; lactation; D2 antagonist; H2 antagonist; proton pump inhibitor

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2021
• Tom: Vol. 33, no. 1
• Strony: 11--24
• Opis fizyczny: Bibliogr. 42 poz., rys., tab.

Twórcy

autor

El Sherbiny Dina

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Delta University for Science and Technology, 35712, Gamasa, Egypt
• Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt

autor

Wahba Mary E. K.

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Delta University for Science and Technology, 35712, Gamasa, Egypt
• Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt

Bibliografia

• 1. Gill, S. K.; O’Brien, L.; Koren, G. Dig. Dis. Sci. 2009, 54, 1835.
• 2. Gerson, L. B. Gastro Enterol. Hepatol. 2012, 8, 763.
• 3. United States Pharmacopeial Convention. United States Pharmacopoeia 30; National Formulary 25; US Pharmacopoeial Convention, 2007.
• 4. http://www.who.int/maternal_child_adolescent/topics/newborn/nutrition/breastfeeding/en/.
• 5. “The British Pharmacopoeia” The Stationary Office; London: Electronic version, 2009.
• 6. Brunton, L. L. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 12th ed.; California, United States: Mc-Grow Hill, 2011.
• 7. Sewell, C. A.; Chang, C. Y.; Chehab, M. M.; Nguyen, C. P. Obstet. Gynecol. 2017, 130, 913.
• 8. Hondeghem, L. M.; Logghe, N. H. Drug Saf. 2017, 40, 109.
• 9. Asztalos, E. V.; Camp bell-Yeo, M.; Op da, S.; Ito, S.; Kiss, A.; Knoppert, D. J. Hum. Lact. 2017, 33, 181.
• 10. Paul, C.; Zenut, M.; Dorut, A.; Coudore, M. A.; Vein, J.; Cardot, J. M.; Balayssac, D. J. Hum. Lact. 2015, 31, 57.
• 11. Gabay, M. J. Hum. Lact. 2002, 18, 274.
• 12. Budd, S.; Erdman, S.; Long, D. Clin. Pediatr. 1993, 32, 53.
• 13. Ehrenkrantz, R.; Ackerman, B. Pediatric 1986, 78, 614.
• 14. Gupta, A.; Gupta, P. Clin. Pediatr. 1985, 24, 269.
• 15. Leelakanok, N.; Holcombe, A.; Schweizer, M. L. Clin. Drug Investig. 2016, 36, 97.
• 16. Marzi, M.; Weitz, D.; Avila, A.; Molina, G.; Caraballo, L.; Piskulic, L. Rev. Med. Chil. 2015, 143, 14.
• 17. Rumore, M. M. Int. J. Case Rep. Images 2012, 3, 1.
• 18. Khasawneh, F. T.; Shankar, G. S. Cardiol. Res. Pract. 2014, 273, 60.
• 19. Hughes, D. G.; Dowling, E. A.; De Meersman, R. E.; Garnett, W. R.; Karnes, H. T. J. Clin. Pharmacol. 1989, 29, 472.
• 20. Halabi, A.; Kirch, W. Scand. J. Gastroenterol. 1992, 27, 753.
• 21. Lázaro, A. M. P.; Cristóbal, C.; Franco-Peláez, J. A.; Tarín, N.; Aceña Á.; Carda, R.; Huelmos, A.; Martín-Mariscal, M. L.; Fuentes-Antras, J.; Martínez-Millá, J.; Alonso, J.; Lorenzo, Ó.; Egido, J.; López-Bescós, L.; Tuñón, J. PLoS One. 2017, 12, 1.
• 22. Sossalla, S.; Schotola, H.; Schmitto, J.; Toischer, K.; Sohns, C.; Schw€orer, H.; Hasenfuss, G.; Maier, L.; Schillinger, W. J. Cardiovasc. Surg. (Torino) 2011, 52, 437.
• 23. El-Charabaty, E.; Saifan, C.; Abdallah, M.; Naboush, A.; Glass, D.; Azzi, G.; Azzi, Y.; Khan, A.; Baydoun, H.; Rondla, C.; Parekh, N.; El-Sayegh, S. Int. J. Gen. Med. 2013, 6, 515.
• 24. Wan, E. W-X; Davey, K.; Sharp, M. P.; Hartmann, P. E.; Simmer, K.; Ilett, K. F. Br. J. Clin. Pharmacol. 2008, 66, 283.
• 25. Zhou, J.; Yuan ,Y.; Li, Q.; Wang, K.; Li, Z.; Zhang, H. Comput. Cardiol. 2015, 42, 1085.
• 26. Tonini, M.; De Ponti, F.; Di Nucci, A.; Crema, F. Aliment. Pharmacol. Ther. 1999, 13, 1585.
• 27. Sugiyama, A.; Satoh, Y.; Shiina, H.; Takeda, S.; Hashimoto, K. J. Cardiovas. Pharmacol. 2002, 40, 235.
• 28. Kugelberg, F. C.; Druid, H.; Carlsson, B.; Ahlner, J.; Bengtsson, F. J. Anal. Toxicol. 2004, 28, 631.
• 29. Beale, J. M.; Block, J. H. Organic Medicinal and Pharmaceutical Chemistry, 12th ed.; London: Wolters Kluwer, Lippincott Williams & Wilkins, 2010.
• 30. Singh, B.; Kumar, R.; Ahuja, N Crit. Rev. Ther. Drug Carrier Syst. 2004, 22, 27.
• 31. Fonner, D. E.; Buck, J. R.; Banker, G. S. J. Pharm. Sci. 1970, 59, 1587.
• 32. Shek, E.; Ghani, M.; Jones, R. E. J. Pharm. Sci. 1980, 69, 1135.
• 33. Barmpalexis, P.; Kanazeb, F. I.; Georgarakisa, E. J. Pharm. Biomed. Anal. 2009, 49, 1192.
• 34. Marengo, E.; Gennaro, M. C. J. Chromatogr. A 1999, 863, 1.
• 35. Sivakumar, T.; Manavalan, R.; Muralidharan, C.; Valliappan, K. J. Pharm. Biomed. Anal. 2007, 43, 1842.
• 36. Ashiru, D. A. I.; Patel, R.; Basit, A. W. J. Chromatogr. B 2007, 860, 235.
• 37. Thanikachalam, S.; Rajappan, M.; Kannappan, V. Chromatographia 2008, 67, 41.
• 38. Radwan, M. Anal. Lett. 1998, 31, 2397.
• 39. Naguib, I. A.; Abdelkawy,M. Eur. J. ofMed. Chem. 2010, 45, 3719.
• 40. Miller, J. N.; Miller, J. C. Statistics and Chemometrics for Analytical Chemistry; Harlow, England: Prentice Hall/Pearson, 2010.
• 41. Bansal, S.; DeStefano, A. AAPS J. 2007, 9, E109.
• 42. Hartmann, C.; Smeyers-Verbeke, J.; Massart, D. L.; McDowall, R. D. J. Pharm. Biomed. Anal. 1998, 17, 193.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2021).